In pharmaceutical and medical device litigation, the failure-to-warn claim continues to be among the most common causes of action. With respect to pharmaceutical products, the relative ease of asserting this claim stands in stark contrast to the difficulty of proving either a manufacturing or design defect.
Practice Tip: Failure-to-Warn Causation and The Learned Intermediary
In pharmaceutical and medical device litigation, the failure-to-warn claim continues to be among the most common causes of action. This article examines some of the key factors involved in proving causation in a failure-to-warn case, and discusses recent case law in this area.
By
Lori G. Cohen And Daniel I.a. SmulianThis premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.
